Armed with a culture of tackling big problems and an expertise in virology and both small molecule and antibody therapeutics, AbbVie scientists are working to understand future emerging global pandemics.
When COVID-19 stunned the world, the freezers inside AbbVie’s labs swung open.
“While most everyone at AbbVie and the world was working remotely, we had teams in our labs pulling compounds and sending them to be tested to see if any had the potential to fight COVID-19,” said Steve Elmore, Ph.D., Vice President, Drug Discovery and Science Technology at AbbVie. “These teams are our front-line, working in shifts often seven days a week. Very early on they were working to identify appropriate compounds.”